---
title: "Maternal Vitamin D Status and Preeclampsia Risk in Kenyan Pregnant Women: A Matched Case–Control S"
id: "plos-one-12-maternal-serum-vitamin-d-levels-and-preeclampsia-among-kenyan-pregnant-women-a"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-12-maternal-serum-vitamin-d-levels-and-preeclampsia-among-kenyan-pregnant-women-a"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0358781"
published_at: "2026-09-22T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Maternal Vitamin D Status and Preeclampsia Risk in Kenyan Pregnant Women: A Matched Case–Control S
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-12-maternal-serum-vitamin-d-levels-and-preeclampsia-among-kenyan-pregnant-women-a
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0358781)
- **Published At:** 2026-09-22T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- This matched case-control study at Moi Teaching and Referral Hospital, Eldoret, Kenya evaluated the relationship between maternal serum **25-hydroxyvitamin D (25(OH)D)** concentrations and preeclampsia in pregnancies ≥28 weeks gestation. - A total of 118 women were analysed: 59 cases with clinician-confirmed preeclampsia and 59 matched normotensive controls matched by age, parity and gestational age. - Serum 25(OH)D was measured at enrolment; vitamin D status was categorised as **suboptimal** (<50 nmol/L) versus sufficient (≥50 nmol/L) per commonly used thresholds. - Median 25(OH)D was lower in preeclampsia cases than controls (67.1 vs 77.6 nmol/L), and a larger proportion of cases had suboptimal vitamin D (32.2% vs 6.8%). - In conditional logistic regression accounting for matching, suboptimal vitamin D was associated with increased odds of preeclampsia (OR 8.0; 95% CI 1.84–34.78; P = 0.006). - Each 10 nmol/L decrease in serum 25(OH)D was associated with a 29% higher odds of preeclampsia (OR 1.29; 95% CI 1.09–1.54; P = 0.004). - The authors suggest potential value in antenatal screening for **vitamin D** status and recommend further research on vitamin D supplementation as a preventive strategy for preeclampsia, noting the need for context-specific data from African populations. - The study was conducted across dry and wet seasons to reduce seasonal bias, was powered as a pilot with 59 matched pairs, and was registered in the Pan African Clinical Trial Registry. Funding and other administrative details are reported in the source.
## Clinical Analysis & Structured Key Points
Maternal serum vitamin D levels and preeclampsia among Kenyan pregnant women: A matched case-control study | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Peer Review Reader Comments Figures Figures Abstract Background Preeclampsia accounts for about one in five direct maternal deaths in Kenya. Low vitamin D levels have been linked to its pathophysiology. Despite this, context‑specific data from African populations remain limited. The study aimed to determine the association between maternal serum 25-hydroxyvitamin D [25(OH)D] concentrations (nmol/L) in pregnancy and the risk of preeclampsia in a Kenyan population. Methods A matched case-control study was conducted at Moi Teaching and Referral Hospital, Kenya. A total of 118 women with confirmed viable intrauterine pregnancies at ≥28 weeks’ gestation were analysed. Fifty-nine women with preeclampsia (cases) and 59 controls were matched by parity, gestation, and age. Serum 25(OH)D was quantified. Vitamin D status was categorised as suboptimal (<50 nmol/L) or sufficient (≥50 nmol/L) status. The association between vitamin D status and preeclampsia was assessed using conditional logistic regression. Odds ratios (ORs) with 95% confidence intervals (CIs) were presented. Results Median serum 25(OH)D was significantly lower in preeclampsia cases compared with controls [67.1 nmol/L (interquartile range 47.8–84.0) vs. 77.6 nmol/L (62.4–99.7); P = 0.001]. Suboptimal vitamin D levels (<50 nmol/L) were observed in 32.2% of preeclampsia cases versus 6.8% of controls ( P = 0.002). In conditional logistic regression accounting for matching, women with suboptimal vitamin D had higher odds of preeclampsia (OR 8.0; 95% CI: 1.84–34.78; P = 0.006). Each 10 nmol/L decrease in serum 25(OH)D was associated with a 29% increase in preeclampsia odds (OR 1.29; 95% CI: 1.09–1.54; P = 0.004). Conclusions In this study, suboptimal maternal serum vitamin D status demonstrated a significant association with preeclampsia. There is potential value in antenatal screening for vitamin D status. Findings support further research into vitamin D supplementation as a preventive intervention for preeclampsia. Trial registration Pan African Clinical Trial Registry ( PACTR202505516303679 ). Citation: Asaso Omwodo K, Kimani JN, Nicodemus K, Kioko DM, Georgieva A (2026) Maternal serum vitamin D levels and preeclampsia among Kenyan pregnant women: A matched case-control study. PLoS One 21(9): e0358781. https://doi.org/10.1371/journal.pone.0358781 Editor: Maria Christine Magnus, Norwegian Institute of Public Health: Folkehelseinstituttet, NORWAY Received: March 31, 2026; Accepted: September 6, 2026; Published: September 22, 2026 Copyright: © 2026 Asaso Omwodo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The de-identified data supporting the study findings are available as S3 File . Funding: This work was supported by the Bill & Melinda Gates Foundation [grant ID: INV-033705], awarded to Kimbley Asaso Omwodo as part of the Supporting Women in Science (SWIS) programme at the Aga Khan University-Institute for Global Health and Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: The authors have declared that no competing interests exist. Introduction Hypertensive disorders of pregnancy (HDP) refer to a group of medical disorders characterised by high blood pressure occurring during pregnancy. HDP affects up to 10% of pregnancies worldwide [ 1 ]. According to the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy, HDP is classified into four categories: chronic hypertension, preeclampsia (and related disorders: eclampsia and haemolysis, elevated liver enzymes, low platelets [HELLP] syndrome), preeclampsia superimposed on chronic hypertension and gestational hypertension [ 2 ]. In Kenya, approximately 1 in 5 direct maternal deaths result from hypertensive disorders, including preeclampsia [ 3 ]. Preeclampsia (PE) aetiology can be divided into two distinct phases. The first phase is characterised by defective placentation. The progression into the second phase is marked by decreased vascularisation occurring at the placental site, which initiates a maternal inflammatory response. PE modifies angiogenic as well as antiangiogenic factors, e.g., serum placental growth factor (PIGF), soluble fms-like tyrosine kinase 1 (sFlt-1), and soluble endoglin (sENG) [ 1 ]. Vitamin D is a family of chemically related secosteroid hormones. It is synthesised primarily in the skin following exposure to UVB radiation from sunlight (wavelength, 290–315 nm). Solar ultraviolet B radiation infiltrates the skin and converts 7-dehydrocholesterol into provitamin D3, which is quickly transformed into vitamin D3. Vitamin D from both cutaneous synthesis and dietary intake is metabolised in the liver into 25-hydroxyvitamin D (25(OH)D), a vitamin D status biomarker, and into 1,25-dihydroxyvitamin D (1,25(OH) 2 D). Although no consensus has been reached on vitamin D status definitions, the Endocrine Society mentions serum 25(OH)D < 20 ng/mL (50 nmol/L) as a common threshold in studies [ 4 ]. In contrast, the Institute of Medicine (IOM) defines deficiency as concentrations below 12 ng/mL (30 nmol/L) and insufficiency as <20 ng/mL (<50 nmol/L) [ 5 ]. Pregnant women are a population at increased risk of vitamin D deficiency. Factors such as inadequate intake of vitamin D, high Body Mass Index (BMI), and a poor-quality diet further heighten this risk. Several mechanisms can elucidate the protective effects of vitamin D in PE. Vitamin D modulates pro-inflammatory responses and also contributes to blood pressure reduction through the renin-angiotensin system (RAAS) [ 6 , 7 ]. A systematic review in 2020 that included pooled data from twenty-seven randomised controlled trials (RCTs) involving 4,777 participants reported that vitamin D supplementation resulted in a 63% risk reduction in the occurrence of PE [ 8 ]. Even so, the studies included in the review did not strictly select participants on the basis of vitamin D status, nor did they evaluate the achievement of optimum vitamin D levels post-supplementation. The authors also noted that the results could not be generalised to an African population, given the absence of studies that included this cohort. A more recent meta-analysis of 33 RCTs (n = 10,613) similarly reported a 45% reduction in preeclampsia risk with supplementation [ 9 ]. Notably, the analysis included only one study from Africa (Congo). Genetic and phenotypic diversity in vitamin D metabolism has been observed among different races, with individuals of European ancestry exhibiting higher vitamin D concentrations [ 10 ]. Skin pigmentation negatively influences vitamin D synthesis, as melanin acts as an absorbent filter (scattering UVR), reducing the efficiency of vitamin D production by UV induction and subsequent circulating levels of 25(OH)D [ 11 , 12 ]. Mogire et al. observed that many African countries lacked studies measuring vitamin D levels [ 13 ]. This study aimed to ascertain the proportion of vitamin D deficiency among parturients with viable pregnancies and to compare the vitamin D levels between women with and without pre-eclampsia. By generating context-specific evidence, the study results would provide insight into whether antenatal vitamin D screening warrants further investigation (as a potential component of PE risk stratification) in Kenya. Objectives: To describe the proportion of vitamin D deficiency among the study sample of women with viable pregnancy at the Moi Teaching and Referral Hospital (MTRH). To compare vitamin D status among pregnant women with and without PE. Methods Study design and setting We conducted a single-centre matched case-control study at MTRH in Eldoret, Kenya (elevation 2,100 metres above sea level). MTRH is a public multi-speciality tertiary healthcare facility with about 12,000 deliveries annually. The referral population includes the western Kenya region, parts of eastern Uganda, southern Sudan, northern Tanzania, and the Democratic Republic of Congo (DRC). Participant recruitment spanned from 1 August 2025 to 31 January 2026. Both dry (August to October) and wet (November to January) seasons were covered to mitigate seasonal variation in vitamin D status. Eligible participants were screened consecutively and enrolled upon admission to the MTRH antenatal ward (ANW) or labour ward (LW) unit. Maternal serum 25(OH)D was measured at enrolment. Data collection occurred concurrently with recruitment. Research was conducted in accordance with the protocol previously published [ 14 ]. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were used in manuscript preparation. The completed STROBE checklist is provided as S1 File . Study size The study was conceptualised as a pilot investigation to generate preliminary context-specific evidence on vitamin D status and PE in a Kenyan population. Based on prior African studies [ 13 ]; fifty-nine case-control pairs would provide 80% power to detect a 25-percentage-point difference in deficiency prevalence between groups, using a two-proportion comparison at α = 0.05. The target sample size was inflated to 120 participants to account for potential attrition. Participants Cases were pregnant women with viable pregnancies (≥28 weeks gestation) diagnosed with PE. Controls comprised normotensive pregnant women (blood pressure <140/90 mmHg without proteinuria). They were concurrently recruited from the same hospital wards and matched to cases by maternal age (±3 years), gestational age (±1 week), and parity (0, 1–3, ≥ 4). The selected matching factors were established risk factors for PE and potential confounders of the association between vitamin D status and PE [ 15 , 16 ]. Ascertainment of cases and controls was performed by trained research assistants who conducted daily reviews of ward admission registers. This was done to ensure standardised diagnostic verification using the facility protocols. Hospital-based controls supported comparable healthcare access. Eligibility criteria Inclusion criteria were (a) maternal age of ≥ 18 years at the time of consent, (b) confirmed singleton pregnancy of 28 weeks gestation or greater (confirmed by ultrasound), (c) delivery at MTRH, and (d) ability to provide written informed consent. Exclusion criteria included (a) pre-existing chronic kidney disease, (b) pre-existing parathyroid conditions, (c) those on cardiac medication, (d) pre-existing thrombophilia, (e) participating in a similar interventional study. Definitions PE was defined prospectively according to the guidelines of the International Society for the Study of Hypertension in Pregnancy [ 17 ]; i.e., new-onset hypertension, defined as systolic blood pressure of 140 mmHg or greater and/or diastolic blood pressure of 90 mmHg or greater (based on an average of two measurements) in a patient who was previously normotensive, accompanied by at least one other symptom and sign related to PE. These symptoms and signs include: Proteinuria (≥300 mg/24 hours or more than 0.3 g/day), Acute kidney injury (creatinine levels at or greater than 90 μmol/L), Liver involvement (elevated transaminases, for example, ALT or AST exceeding 40 IU/L), Neurological symptoms (such as altered mental status, blindness, stroke, severe headaches, persistent visual scotomata), Haematological abnormalities (including thrombocytopenia, i.e., platelet count below 150,000/μL, disseminated intravascular coagulation, and haemolysis), Cardiorespiratory complications (pulmonary oedema, myocardial ischaemia or infarction, oxygen saturation below 90%, use of 50% or more inspired oxygen for over an hour, intubation not related to caesarean delivery), or Uteroplacental dysfunction (foetal growth restriction, angiogenic imbalance, placental abruption) occurring after 20 weeks gestation Vitamin D status was categorised based on Institute of Medicine (IOM) guidelines [ 5 ]. Categories were deficient (<30 nmol/L), insufficient (30–49 nmol/L), and sufficient (≥50 nmol/L). The Endocrine Society notes that vitamin D status of < 50 nmol/L is associated with increased risk of hypertensive disorders of pregnancy [ 4 ]. Similar to Gidlof et al., categorisation for analysis was also done according to suboptimal (<50 nmol/L) versus sufficient (≥50 nmol/L) status [ 18 ]. Covariates: Demographic factors, including maternal age, parity, gestational age, and pre-pregnancy BMI, were collected. Gestational age was calculated from the first day of the last menstrual period. Parity was defined as the number of times the participant has given birth to a foetus of ≥ 24 weeks gestational age, regardless of pregnancy outcome. BMI was calculated as weight in kilograms divided by height in metres squared (kg/m 2 ). Participant and medical files reporting relevant medical diagnoses (chronic hypertension, diabetes) were also collected. Data were collected using structured interviewer-administered questionnaires. Biological sampling and assessment of serum vitamin D: Approximately 5 mL of maternal blood was obtained via venipuncture into serum separator tubes (Becton Dickinson, Franklin Lakes, NJ, USA). Laboratory technicians processing the samples were blinded to case/control status. Samples were allowed to clot at room temperature for 30 minutes, then placed in an insulated cool box for transportation to the Cerba Lancet laboratory (ISO15189 accredited) for processing. The transportation temperature of the cool box was maintained at 2–8°C. The transportation took place within 2 hours. Serum 25(OH)D levels (combined D2 and D3) were quantified using High-Performance Liquid Chromatography (HPLC). A photodiode array detector (ClinRep HPLC Complete Kit, Recipe, München, Germany) was used. The Cerba Lancet laboratory participates in the Vitamin D External Quality Assessment Scheme (DEQAS) [ 19 ]. Bias Patients with pre-existing conditions affecting vitamin D metabolism were excluded to reduce selection bias (i.e., chronic kidney disease, parathyroid conditions and thrombophilia). Measurement bias was reduced by laboratory technicians processing vitamin D assays being blinded to case/control status. Matching study design and conditional logistic regression (at analysis) addressed confounding. Statistical analysis Data analysis was done using Stata software version 19.0 (StataCorp LLC, College Station, TX, USA). Normality of continuous variables was assessed using the Kolmogorov-Smirnov test. Baseline characteristics were summarised as means with standard deviations (SD) or medians with interquartile ranges (IQR) for continuous variables as appropriate. Categorical variables were presented as frequencies with percentages. Baseline characteristics were summarised and compared by PE status. Differences in continuous variables were compared using paired t-tests for normally distributed continuous variables, Wilcoxon signed-rank tests for skewed continuous variables, and McNemar's test or Fisher's exact test for categorical variables. Matched study design was accounted for. Vitamin D status was categorised a priori [ 4 , 5 ]. Conditional logistic regression (to account for the matching factors) was used to assess the association between vitamin D status and PE. Dose–response analysis was performed treating serum 25(OH)D as a continuous variable. Missing data were handled by complete case analysis; matched pairs with missing covariate data in either member were excluded from adjusted models. Significance was set at p-value < 0.05 (two-sided). Ethical considerations The study protocol has been previously published [ 14 ] and prospectively registered as an observational study with the Pan African Clinical Trial Registry (PACTR). Registration number PACTR202505516303679. Review and ethical approval were obtained from the Institutional Review and Ethics Committee of Moi University/MTRH (IREC approval number 0005019). Written authorisation was obtained from the management of MTRH to conduct the study (reference ELD/MTRH/R&P/10/2/V.2/2010). A research licence was also granted from the National Commission for Science, Technology, and Innovation (NACOSTI) Kenya before commencement of the study (Licence number NACOSTI/P/25/417821). Written informed consent was taken from each participant before enrolment into the study. Autonomy was upheld by providing participants all the necessary information and freedom to withdraw from the study at any point without need for justification. Results Participant characteristics and vitamin D status Between August 2025 and January 2026, 135 women with pregnancies ≥28 weeks were screened for eligibility. Five did not meet inclusion (3 had parathyroid conditions, 2 had chronic kidney disease) and 6 declined participation. Reasons for declining included anxiety about needles and excessive blood loss (3) and perceived lack of direct benefit (2). One woman in labour declined due to competing clinical priorities. All 124 women meeting eligibility were enrolled into the study. Six enrolled participants (3 cases, 3 controls) were excluded post-hoc because no eligible 1:1 match could be identified. Excluded participants did not differ systematically from included participants by demographic characteristics or vitamin D status ( S2 File ). The final analytic sample consisted of 118 participants (59 matched case-control pairs) ( Fig 1 ). Download: PNG larger image TIFF original image Fig 1. Study flow diagram showing participant selection. Matching was performed on maternal age (±3 years), parity (0, 1–3, ≥ 4), and gestational age at delivery (±1 week). https://doi.org/10.1371/journal.pone.0358781.g001 Matching achieved comparability for mean maternal age, gestational age and parity. Sociodemographic factors were also similarly distributed between groups. Women with PE were more likely to be referred from peripheral facilities compared to controls (78.0% vs. 39.0%; P < 0.001). This reflects the referral nature of the cases in this study group. Mean maternal serum 25(OH)D concentrations were lower among women with PE compared to controls (64.3 ± 24.5 nmol/L vs. 82.5 ± 28.8 nmol/L). Baseline characteristics by PE status are presented in Table 1 . Download: PNG larger image TIFF original image Table 1. Baseline maternal characteristics by preeclampsia status. https://doi.org/10.1371/journal.pone.0358781.t001 Association between vitamin D deficiency and PE Median maternal serum 25(OH)D concentration was 67.1 nmol/L (IQR 47.8–84.0) in PE cases vs. 77.6 nmol/L (IQR 62.4–99.7) in controls; means were 64.3 ± 24.5 vs 82.3 ± 28.6 nmol/L. Using the IOM classification, deficiency (<30 nmol/L) was observed in 5 (8.5%) PE cases vs. 1 (1.7%) control and insufficiency (30–49 nmol/L) in 14 (23.7%) vs. 3 (5.1%) controls. Sufficient vitamin D levels (≥ 50 nmol/L) were present in 40 (67.8%) preeclampsia cases versus 55 (93.2%) controls. Table 2 presents the distribution of maternal serum 25(OH)D concentration by PE status. Download: PNG larger image TIFF original image Table 2. Association between vitamin D deficiency and preeclampsia (n = 118). https://doi.org/10.1371/journal.pone.0358781.t002 Fig 2 presents individual and paired maternal serum 25(OH)D concentrations in cases and controls. Download: PNG larger image TIFF original image Fig 2. Individual and paired maternal serum 25(OH)D concentrations in cases and controls. In
## Related Clinical Research

- [Iron-related Parameters and Sepsis-associated Acute Kidney Injury — Source Content Not Available](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-association-of-iron-related-parameters-with-the-development-of-sepsis.md)
- [Obesity-related multimorbidity patterns and reduced quality of life in Iranian adults](https://medichelpline.com/clinical-feed/bmj-open-19-obesity-related-patterns-of-multimorbidity-and-their-association-with-health.md)
- [Machine learning and deep learning prediction of hypertension and key risk factors in Bangladesh](https://medichelpline.com/clinical-feed/plos-one-12-machine-learning-and-deep-learning-based-prediction-of-hypertension-and.md)
- [Dyslipidemia care in Japan before and after the 2024 fee revision: nationwide claims analysis](https://medichelpline.com/clinical-feed/plos-one-19-real-world-patterns-of-dyslipidemia-care-before-and-after-a-national-fee.md)
- [Nintedanib-Linked Glomerular Endothelial Injury and Secondary Collapsing FSGS: SGLT2 Inhibitor as](https://medichelpline.com/clinical-feed/pubmed-42674550.md) (DOI: 10.1111/nep.70274)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.